1 |
Woelderink, A., Ibarreta, D., Hopkins, M. M. and Rodriguez-Cerezo, E. (2006). The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies. Pharmacogenomics Journal 6(1), 3-7
DOI
ScienceOn
|
2 |
Kurzawski, M., Dziewanowski, K., Gawronska-Szklarz, B., Domanski, L. and Drozdzik, M. (2005). The impact of thiopurine s-methyltransferase polymorphism on azathioprineinduced myelotoxicity in renal transplant recipients. Therapeutic Drug Monitoring 27(4), 435-41
DOI
ScienceOn
|
3 |
Mummaneni, P., Amur, S. G., Goodsaid, F., Rudman, A. and Frueh, F. W. (2006). Genomic biomarkers in FDA-approved drug labels (abst). Journal of Clinical Pharmacology 46, 1088
|
4 |
Lehmann, D. F., Medicis, J. J. and Franklin, P. D. (2003). Polymorphisms and the pocketbook: the cost-effectiveness of cytochrome P450 2C19 genotyping in the eradication of Helicobacter pylori infection associated with duodenal ulcer. Journal of Clinical Pharmacology 43(12), 1316-23
DOI
|
5 |
MacPhee, I. A. M., Fredericks, S., Tai, T., Syrris, P., Carter, N. D., Johnston, A., Goldberg, L. and Holt, D. W. (2004). The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation.[see comment]. American Journal of Transplantation 4(6), 914-9
DOI
ScienceOn
|
6 |
Marra, C. A., Esdaile, J. M. and Anis, A. H. (2002). Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. Journal of Rheumatology 29(12), 2507-12
|
7 |
Rieder, M. J., Reiner, A. P., Gage, B. F., Nickerson, D. A., Eby, C. S., McLeod, H. L., Blough, D. K., Thummel, K. E., Veenstra, D. L. and Rettie, A. E. (2005). Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. New England Journal of Medicine 352(22), 2285-93
DOI
ScienceOn
|
8 |
Rolan, P., Atkinson, A. J., Jr., Lesko, L. J., Scientific Organizing, C. and Conference Report, C. (2003). Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development. Clinical Pharmacology & Therapeutics 73(4), 284-91
DOI
ScienceOn
|
9 |
Sconce, E. A., Khan, T. I., Wynne, H. A., Avery, P., Monkhouse, L., King, B. P., Wood, P., Kesteven, P., Daly, A. K. and Kamali, F. (2005). The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106(7), 2329-33
DOI
ScienceOn
|
10 |
Veenstra, D. L., You, J. H. S., Rieder, M. J., Farin, F. M., Wilkerson, H.-W., Blough, D. K., Cheng, G. and Rettie, A. E. (2005). Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenetics & Genomics 15(10), 687-91
DOI
|
11 |
Mushiroda, T., Ohnishi, Y., Saito, S., Takahashi, A., Kikuchi, Y., Saito, S., Shimomura, H., Wanibuchi, Y., Suzuki, T., Kamatani, N. and Nakamura, Y. (2006). Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. Journal of Human Genetics 51(3), 249-53
DOI
|
12 |
Racine, D. P. (2006). Reliable effectiveness: a theory on sustaining and replicating worthwhile innovations. Administration & Policy in Mental Health 33(3), 356-87
DOI
|
13 |
Wolfberg, A. J. (2006). Genes on the Web--direct-to-consumer marketing of genetic testing. New England Journal of Medicine 355(6), 543-5
DOI
ScienceOn
|
14 |
Frueh, F. W., Goodsaid, F., Rudman, A., Huang, S. M. and Lesko, L. J. (2005). The need for education in pharmacogenomics: a regulatory perspective. Pharmacogenomics Journal 5(4), 218-20
DOI
ScienceOn
|
15 |
You, J. H. S., Chan, F. W. H., Wong, R. S. M. and Cheng, G. (2004). The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis. Thrombosis & Haemostasis 92(3), 590-7
|
16 |
Zheng, H., Webber, S., Zeevi, A., Schuetz, E., Zhang, J., Bowman, P., Boyle, G., Law, Y., Miller, S., Lamba, J. and Burckart, G. J. (2003). Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. American Journal of Transplantation 3(4), 477-83
DOI
ScienceOn
|
17 |
Zheng, H., Zeevi, A., Schuetz, E., Lamba, J., McCurry, K., Griffith, B. P., Webber, S., Ristich, J., Dauber, J., Iacono, A., Grgurich, W., Zaldonis, D., McDade, K., Zhang, J. and Burckart, G. J. (2004). Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. Journal of Clinical Pharmacology 44(2), 135-40
DOI
|
18 |
Burckart, G. J. and Liu, X. I. (2006). Pharmacogenetics in transplant patients: can it predict pharmacokinetics and pharmacodynamics? Therapeutic Drug Monitoring 28(1), 23-30
DOI
ScienceOn
|
19 |
Evans, B. J., Flockhart, D. A. and Meslin, E. M. (2004). Creating incentives for genomic research to improve targeting of therapies. Nature Medicine 10(12), 1289-91
DOI
ScienceOn
|
20 |
Evans, W. E. (2004). Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Therapeutic Drug Monitoring 26(2), 186-91
DOI
|
21 |
Herman, D., Locatelli, I., Grabnar, I., Peternel, P., Stegnar, M., Mrhar, A., Breskvar, K. and Dolzan, V. (2005). Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics Journal 5(3), 193-202
DOI
ScienceOn
|